SITE002-0237

SITE002 (USA) › SITE002-0237

SITE002-0237

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2026-06-03

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-18 (study day 32); relationship: not assessed

mild assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 15); relationship: not assessed

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.